CN Patent

CN103370314A — 作为用于治疗癌症疾病的fgfr激酶抑制剂的取代苯并吡嗪衍生物

Assigned to Astex Therapeutics Ltd · Expires 2013-10-23 · 13y expired

What this patent protects

本发明涉及新型喹喔啉衍生物化合物、涉及包含所述化合物的药物组合物、涉及所述化合物的制备方法以及涉及所述化合物在疾病，例如癌症治疗中的用途。

USPTO Abstract

本发明涉及新型喹喔啉衍生物化合物、涉及包含所述化合物的药物组合物、涉及所述化合物的制备方法以及涉及所述化合物在疾病，例如癌症治疗中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN103370314A
Jurisdiction
CN
Classification
—
Expires
2013-10-23
Drug substance claim
No
Drug product claim
No
Assignee
Astex Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.